Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/136261
Full metadata record
DC FieldValueLanguage
dc.creatorFreitas, R
dc.creatorBasto, A
dc.creatorAlmeida, S
dc.creatorSantos, RF
dc.creatorGonçalves, CM
dc.creatorCorria-Osorio, J
dc.creatorCarvalho, T
dc.creatorCarmo, AM
dc.creatorOliveira, V
dc.creatorLeon, K
dc.creatorGraca, L
dc.date.accessioned2021-09-20T10:52:28Z-
dc.date.available2021-09-20T10:52:28Z-
dc.date.issued2019
dc.identifier.issn2352-3964
dc.identifier.urihttps://hdl.handle.net/10216/136261-
dc.description.abstractIn recent years molecules involved on the immune synapse became successful targets for therapeutic immune modulation. CD6 has been extensively studied, yet, results regarding CD6 biology have been controversial, in spite of the ubiquitous presence of this molecule on virtually all CD4 T cells. We investigated the outcome of murine and human antibodies targeting CD6 domain 1. We found that CD6-targeting had a major impact on the functional specialization of CD4 cells, both human and murine. Differentiation of CD4 T cells towards a Foxp3+ Treg fate was prevented with increasing doses of anti-CD6, while Th1 polarization was favoured. No impact was observed on Th2 or Th17 specialization. These in vitro results provided an explanation for the dose-dependent outcome of in vivo anti-CD6 administration where the anti-inflammatory action is lost at the highest doses. Our data show that therapeutic targeting of the immune synapse may lead to paradoxical dose-dependent effects due to modification of T cell fate.
dc.description.sponsorshipFunded by UID/BIM/50005/2019, project funded by Fundação para a Ciência e a Tecnologia (FCT) / Ministério da Ciência, Tecnologia e Ensino Superior (MCTES) throught Fundos do Orçamento do Estado, pela Fundação para a Ciência e a Tecnologia (FCT) ( PTDC/DTP-FTO/3080/2014 ); and by the project SRecognite Infect - ERA/0003/2015 using national funds through FCT . Funders did not have a role in study design, data collection, analysis, and interpretation, or in the writing of the manuscript.
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofEBioMedicine, vol.47, p. 427-435
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectCD4 T cells
dc.subjectCD6
dc.subjectEAE
dc.subjectFoxp3
dc.subjectT-cell polarization
dc.subjectTreg cells
dc.subject.meshAnimals
dc.subject.meshAntigens, CD / metabolism
dc.subject.meshAntigens, Differentiation, T-Lymphocyte / metabolism
dc.subject.meshBiomarkers
dc.subject.meshCD4-Positive T-Lymphocytes / cytology
dc.subject.meshCD4-Positive T-Lymphocytes / immunology
dc.subject.meshCD4-Positive T-Lymphocytes / metabolism
dc.subject.meshCell Adhesion Molecules, Neuronal / metabolism
dc.subject.meshCell Differentiation
dc.subject.meshFetal Proteins / metabolism
dc.subject.meshHumans
dc.subject.meshLymphocyte Activation
dc.subject.meshMice
dc.subject.meshMice, Transgenic
dc.subject.meshT-Lymphocyte Subsets / immunology
dc.subject.meshT-Lymphocyte Subsets / metabolism
dc.titleModulation of CD4 T cell function via CD6-targeting
dc.typeArtigo em Revista Científica Internacional
dc.contributor.uportoInstituto de Investigação e Inovação em Saúde
dc.identifier.doi10.1016/j.ebiom.2019.08.008
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S2352396419305249?via%3Dihub
Appears in Collections:I3S - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
10.1016-j.ebiom.2019.08.008.pdf2.54 MBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons